Conclusion : This meta‐ analysis has shown that fibrate treatment  significantly decreases fasting plasma glucose , insulin levels , and HOMA‐IR indicating additional clinical therapeutic benefits .
Aims : The aim of this meta‐ analysis of r and omized placebo‐controlled clinical trials was to assess the effect of fibrates on glycemic parameters .
Proof of concept study: does fenofibrate have a role in sleep apnoea syndrome?
Abstract Objective : To investigate the effect of fenofibrate on  sleep apnoea indices . Methods : Proof-of-concept study comprising a placebo run-in period ( 1 week , 5 weeks if fibrate washout was required ) and a 4-week r and omized , double-blind treatment period . Thirty-four subjects ( mean age 55 years , body mass index 34 kg/m2 , fasting triglycerides 3.5 mmol/L ) with diagnosed sleep apnoea syndrome not treated with continuous positive airways pressure were enrolled and r and omized to once daily treatment with fenofibrate ( 145 mg NanoCrystal ® tablet ) or placebo .  Overnight polysomnography , computerized attention/vigilance tests and blood sampling for measurement of lipids , insulin , fasting plasma glucose and fibrinogen were performed at the end of each study period . Clinical trial registration : NCT00816829 . Main outcome measures : As this was an exploratory study , a range of sleep variables were evaluated . The apnoea/hypopnoea index ( AHI ) and percentage of time spent with arterial oxygen saturation ( SpO2 ) < 90 % were relevant as they have been evaluated in other clinical trials . Other variables included total apnoeas , hypopnoeas and oxygen desaturations , and non-cortical micro-awakenings related to respiratory events per hour . Results : Fenofibrate treatment significantly reduced the percentage of time with SpO2 < 90 % ( from 9.0 % to 3.5 % vs. 10.0 % to 11.5 % with placebo , p = 0.007 ) , although there was no significant change in the AHI ( reduction vs. control 14 % ( 95%CI −47 to 40 % , p = 0.533 ) . Treatment reduced obstructive apnoeas ( by 44 % , from 18.5 at baseline to 15.0 at end of treatment vs. 29.0 to 30.5 on placebo , p = 0.048 ) , and non-cortical micro-awakenings per hour ( from 23.5 to 18.0 vs. 24.0 to 25.0 with placebo , p = 0.004 ) . Other sleep variables were not significantly influenced by fenofibrate . Key limitations : Exploratory study in patients with mild to moderate sleep apnoea , limited treatment duration ; concomitant hypnotic treatment ( 35 % ) ; lack of correction for multiplicity of testing . Conclusions : The consistent direction of change in sleep indices in this proof-of-concept study may support further investigation of fenofibrate in moderate to severe sleep apnoea syndrome
Conclusion : This meta‐ analysis has shown that fibrate treatment  significantly decreases fasting plasma glucose , insulin levels , and HOMA‐IR indicating additional clinical therapeutic benefits .
Aims : The aim of this meta‐ analysis of r and omized placebo‐controlled clinical trials was to assess the effect of fibrates on glycemic parameters .